CMS4 has the worst prognosis out of the four subtypes of CRC, and therapy that targets CMS4-like TGF-β-activated CRC paves the route for overcoming the tumor microenvironmental interaction that promotes the mesenchymal phenotype. Here, TGFB1 is linked to colorectal carcinoma.